About
Shannon is an Associate in our New York office primarily supporting our Life Sciences Transactions team. She advises companies in the healthcare, pharmaceutical and biotech space on a variety of transactions, including mergers and acquisitions, licensing agreements, commercial agreements and corporate reorganizations.
Prior to becoming a lawyer, Shannon conducted graduate-level quantitative research analyzing the relationship between ecotoxicological factors and human disease. She has also previously worked as a program coordinator for a university digital health center.
Additional Information
- CK Life Sciences on its sale of Polynoma to TransCode Therapeutics and concurrent strategic financing in TransCode.
- Merck on its acquisition of Verona Pharma plc for a total transaction value of approximately $10 billion.
- Standard BioTools on its strategic sale of SomaLogic to Illumina.
- AbbVie on its strategic option-to-license agreement with Simcere Zaiming to develop a novel trispecific antibody candidate in multiple myeloma.
- Merz Therapeutics on its $185 million acquisition of the assets of Acorda Therapeutics, Inc. through a court structured 363 sale process under the U.S. Bankruptcy Code.
- Johnson & Johnson on its $13.1 billion acquisition of Shockwave Medical, Inc.
- Novartis on its exclusive license agreement with Arvinas, Inc. for the global development and commercialization of a prostate cancer treatment.
- Roivant Sciences on its sale of Dermavant to Organon for up to $1.2 billion.
- Cencora (f/k/a AmerisourceBergen) on its $4.6 billion acquisition of Retina Consultants of America.
- AstraZeneca on its acquisition of Gracell Biotechnologies.
Shannon O'Hara
Associate
New York Office
3 World Trade Center
175 Greenwich Street, 51st Floor
10007 New York